Publications by authors named "Libor Havel"

Claim this Profile
D
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study.
Niels Reinmuth, Jonathan W Goldman, Yuanbin Chen, Katsuyuki Hotta, Dmytro Trukhin, Libor Havel

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair, Libor Havel

Lung Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data.
Gabriela Krakorova, Petr Domecky, Jiri Blazek, Milos Pesek, Ondrej Venclicek, Libor Havel

Transl Lung Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Nivolumab in Resectable Lung Cancer.
Tina Cascone, Mark M Awad, Jonathan D Spicer, Jie He, Shun Lu, Libor Havel

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Libor Havel

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
Vincent D de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brcic, Libor Havel

Lancet Reg Health Eur· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
Vincent D de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brcic, Libor Havel

Lancet Reg Health Eur· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Libor Havel

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.
Monika Bratova, Jana Skrickova, Magda Matusikova, Karolina Hrabcova, Libor Havel

J Cancer Res Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Libor Havel

Lancet Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel

Lancet Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.
Yuanbin Chen, Luis Paz-Ares, Niels Reinmuth, Marina Chiara Garassino, Galina Statsenko, Libor Havel

JTO Clin Res Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Worse Prognosis in the Symptomatic Patients With Lung Cancer - Czech Multicentric Study.
Miloslav Marel, Zdenka Chladkova, Luis Fernando Casas Mendez, Ondrej Venclicek, Jana Skrickova, Libor Havel

Cancer Diagn Progn· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial.
Milada Zemanova, Marketa Cernovska, Libor Havel, Tomas Bartek, Sarka Lukesova

Cancer Treat Res Commun· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
Ondrej Venclicek, Jana Skrickova, Kristian Brat, Ondrej Fischer, Libor Havel

Anticancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ocular lesion of unknown aetiology.
Marie Drosslerova, Marketa Cernovska, Martina Vasakova, Libor Havel

Breathe (Sheff)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Libor Havel

Lancet Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Jonathan W Goldman, Marina Chiara Garassino, Yuanbin Chen, Mustafa Özgüroğlu, Mikhail Dvorkin, Libor Havel

Lung Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry.
Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Libor Havel

Thorac Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry.
Monika Bratova, Bara Karlinova, Jana Skrickova, Milos Pesek, Vitezslav Kolek, Libor Havel

In Vivo· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Libor Havel

Lancet· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski

N Engl J Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Libor Havel

N Engl J Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Martin Reck, Alexander Luft, Aleksandra Szczesna, Libor Havel, Sang-We Kim

J Clin Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries.
Francesco Grossi, Jaafar Bennouna, Libor Havel, Maximillian Hochmair, Teresa Almodovar

Curr Med Res Opin· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis